Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | protein arginine N-methyltransferase, putative | 0.008 | 0.475 | 1 |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0099 | 1 | 0.5 |
Plasmodium vivax | protein arginine N-methyltransferase 1, putative | 0.008 | 0.475 | 0.5 |
Schistosoma mansoni | protein arginine N-methyltransferase 1 | 0.008 | 0.475 | 1 |
Echinococcus multilocularis | protein arginine methyltransferase | 0.008 | 0.475 | 0.5 |
Echinococcus multilocularis | protein arginine N methyltransferase 8 | 0.008 | 0.475 | 0.5 |
Trichomonas vaginalis | protein arginine N-methyltransferase, putative | 0.008 | 0.475 | 1 |
Leishmania major | arginine N-methyltransferase-like protein | 0.0063 | 0 | 0.5 |
Schistosoma mansoni | protein arginine N-methyltransferase 1 | 0.008 | 0.475 | 1 |
Toxoplasma gondii | histone arginine methyltransferase PRMT1 | 0.008 | 0.475 | 0.5 |
Plasmodium falciparum | protein arginine N-methyltransferase 1 | 0.008 | 0.475 | 0.5 |
Echinococcus granulosus | protein arginine methyltransferase | 0.008 | 0.475 | 0.5 |
Trypanosoma brucei | Protein arginine N-methyltransferase 1 catalytic subunit | 0.0099 | 1 | 0.5 |
Entamoeba histolytica | arginine N-methyltransferase protein, putative | 0.0099 | 1 | 0.5 |
Echinococcus granulosus | protein arginine N methyltransferase 8 | 0.008 | 0.475 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0099 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0099 | 1 | 0.5 |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0099 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | > 100 uM | Cytotoxicity against human HuH7 cells after 3 days | ChEMBL. | 22039920 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.